Market revenue in 2023 | USD 5,912.0 million |
Market revenue in 2030 | USD 6,444.8 million |
Growth rate | 1.2% (CAGR from 2023 to 2030) |
Largest segment | Oseltamivir phosphate |
Fastest growing segment | Baloxavir Marboxil |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Peramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.
oseltamivir phosphate was the largest segment with a revenue share of 27.6% in 2023. Horizon Databook has segmented the Global influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global influenza treatment market , including forecasts for subscribers. This global databook contains high-level insights into Global influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account